Dear Doctor Letter (Rote-Hand-Brief) on Radium 223 dichloride (Xofigo®): increased risk of death and fractures in a randomised clinical trial with Xofigo® used in combination with abiraterone acetate and prednisolone/prednisone
2017.12.12
Active substance: radium 223 dichloride
The company Bayer is circulating information on an increased incidence of deaths and fractures in a randomised clinical trial (15396/ERA-223 study) in patients with chemotherapy-naϊve castration-resistant prostate cancer (CRPC) receiving radium 223 dichloride (Xofigo®) in combination with abiraterone acetate and prednisolone/prednisone.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN